Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV+~* Age 12 to \< 25 years~* History of no or one hepatitis B vaccination~* Not pregnant.~* Females engaging in sexual intercourse must be willing to practice an approved method of birth control throughout the completion of the vaccine phase of the study.~Exclusion Criteria:~* History of \> 1 hepatitis B vaccination~* Serologic evidence of past or present hepatitis B infection: anti-hepatitis B surface antigen (HBsAg), HBs-Ag or anti- hepatitis B core antigen (HBcAg)~* Previous allergic reaction to hepatitis A or B vaccinations or to yeast, thimerosal or aluminum.~* Active opportunistic infection or current treatment for known or suspected active serious bacterial infection at the pre-entry exam.~Presence of any known grade \>= 3 clinical or laboratory toxicity at the time of pre-entry per toxicity tables.~* Anticipation of long-term corticosteroid therapy or within 3 months preceding study randomization. Use of non-steroidal, anti-inflammatory agents and inhaled or topical corticosteroids are allowed.~* Receipt of any restricted medicine listed in the protocol section 8.1.3 within 3 months preceding randomization.~* Receipt of immune globulin product or plasma product within 6 months preceding randomization~* Receipt of licensed blood product or transfusion or any licensed vaccine within 4 weeks preceding randomization.~* Known or suspected diseases of the immune system, other than HIV, or treatment for a malignancy within 3 months of randomization.~* Other serious, acute or chronic medical or surgical conditions must be approved by the protocol chair.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard dose (20 mcg) of Hepatitis B vaccine.
- 2 (Type: ACTIVE_COMPARATOR): 40 mcg of Hepatitis B vaccine
- 3 (Type: ACTIVE_COMPARATOR): 20 mgc of Twinrix

Based on this trial design, predict the completion outcome and termination type (if applicable).